Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.

Ojima, Ayako

Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. [electronic resource] - The American journal of pathology Jan 2013 - 132-41 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1525-2191

10.1016/j.ajpath.2012.09.016 doi


Animals
Arginine--analogs & derivatives
Diabetes Mellitus, Experimental--drug therapy
Diabetic Nephropathies--drug therapy
Drug Evaluation, Preclinical--methods
Exenatide
Gene Expression Regulation, Enzymologic--drug effects
Glucagon-Like Peptide 1--pharmacology
Glucagon-Like Peptide-1 Receptor
Glycation End Products, Advanced--physiology
Humans
Hypertrophy--prevention & control
Hypoglycemic Agents--pharmacology
Kidney--metabolism
Kidney Glomerulus--pathology
Kidney Tubules--metabolism
Macrophages--pathology
Male
Peptides--pharmacology
Protein-Arginine N-Methyltransferases--biosynthesis
RNA, Messenger--genetics
Rats
Rats, Wistar
Reactive Oxygen Species--metabolism
Receptor for Advanced Glycation End Products
Receptors, Glucagon--agonists
Receptors, Immunologic--metabolism
Repressor Proteins--biosynthesis
Venoms--pharmacology